{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:47:14Z","timestamp":1772012834933,"version":"3.50.1"},"reference-count":106,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006152","name":"Josiah Macy Jr. Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.mcna.2018.02.007","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T11:33:37Z","timestamp":1529408017000},"page":"635-652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Office-Based Addiction Treatment in Primary Care"],"prefix":"10.1016","volume":"102","author":[{"given":"E. Jennifer","family":"Edelman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin J.","family":"Oldfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanette M.","family":"Tetrault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2018.02.007_bib1","series-title":"America's need for and receipt of substance use treatment in 2015. The CBHSQ report","author":"Lipari","year":"2013"},{"issue":"12","key":"10.1016\/j.mcna.2018.02.007_bib2","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s11606-017-4140-9","article-title":"Partnering with psychiatry to close the education gap: an approach to the addiction epidemic","volume":"32","author":"Tetrault","year":"2017","journal-title":"J\u00a0Gen Intern Med"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.007_bib3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1370\/afm.2111","article-title":"Now is the time to address substance use disorders in primary care","volume":"15","author":"Saitz","year":"2017","journal-title":"Ann Fam Med"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.007_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1370\/afm.2017","article-title":"Updated priorities among effective clinical preventive services","volume":"15","author":"Maciosek","year":"2017","journal-title":"Ann Fam Med"},{"issue":"9","key":"10.1016\/j.mcna.2018.02.007_bib5","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1001\/jamapsychiatry.2017.2161","article-title":"Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: results from the national epidemiologic survey on alcohol and related conditions","volume":"74","author":"Grant","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.007_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1360-0443.1986.tb00291.x","article-title":"Alcohol-related problems in the primary health care setting: a review of early intervention strategies","volume":"81","author":"Babor","year":"1986","journal-title":"Br J Addict"},{"key":"10.1016\/j.mcna.2018.02.007_bib7","series-title":"Results from the 2013 National survey on drug use and health: summary of national findings","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2014"},{"key":"10.1016\/j.mcna.2018.02.007_bib8","unstructured":"U.S. Preventive Services Task Force. Final recommendation statement: alcohol misuse: screening and behavioral counseling interventions in primary care. 2013. Available at: https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/RecommendationStatementFinal\/alcohol-misuse-screening-and-behavioral-counseling-interventions-in-primary-care. Accessed March 26, 2018."},{"issue":"9","key":"10.1016\/j.mcna.2018.02.007_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.7326\/0003-4819-157-9-201211060-00544","article-title":"Behavioral counseling after screening for alcohol misuse in primary care: a systematic review and meta-analysis for the U.S. Preventive Services Task Force","volume":"157","author":"Jonas","year":"2012","journal-title":"Ann Intern Med"},{"issue":"16","key":"10.1016\/j.mcna.2018.02.007_bib10","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","article-title":"The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test","volume":"158","author":"Bush","year":"1998","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.mcna.2018.02.007_bib11","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/add.12500","article-title":"Lost in translation: the perils of implementing alcohol brief intervention when there are gaps in evidence and its interpretation","volume":"109","author":"Saitz","year":"2014","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.mcna.2018.02.007_bib12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.7326\/0003-4819-159-3-201308060-00652","article-title":"Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U.S. preventive services task force recommendation statement","volume":"159","author":"Moyer","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2018.02.007_bib13","series-title":"Helping patients who drink too much: a clinician's guide","author":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","year":"2005"},{"issue":"Suppl 2","key":"10.1016\/j.mcna.2018.02.007_bib14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/add.13675","article-title":"Screening, brief intervention and referral to treatment: implications of SAMHSA's SBIRT initiative for substance abuse policy and practice","volume":"112","author":"Babor","year":"2017","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.007_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/inr.12096","article-title":"Are nurse-conducted brief interventions (NCBIs) efficacious for hazardous or harmful alcohol use? A systematic review","volume":"61","author":"Joseph","year":"2014","journal-title":"Int Nurs Rev"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.007_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1521-0391.2011.00143.x","article-title":"A\u00a0meta-analysis of the efficacy of nonphysician brief interventions for unhealthy alcohol use: implications for the patient-centered medical home","volume":"20","author":"Sullivan","year":"2011","journal-title":"Am J Addict"},{"key":"10.1016\/j.mcna.2018.02.007_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsat.2015.07.011","article-title":"Local implementation of alcohol screening and brief intervention at five veterans health administration primary care clinics: perspectives of clinical and administrative staff","volume":"60","author":"Williams","year":"2016","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"Suppl 2","key":"10.1016\/j.mcna.2018.02.007_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/add.13653","article-title":"The relative impact of brief treatment versus brief intervention in primary health-care screening programs for substance use disorders","volume":"112","author":"Aldridge","year":"2017","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.mcna.2018.02.007_bib19","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/add.13701","article-title":"Receipt of addiction treatment as a consequence of a brief intervention for drug use in primary care: a randomized trial","volume":"112","author":"Kim","year":"2017","journal-title":"Addiction"},{"issue":"7","key":"10.1016\/j.mcna.2018.02.007_bib20","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/add.12388","article-title":"Should brief interventions in primary care address alcohol problems more strongly?","volume":"109","author":"McCambridge","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.mcna.2018.02.007_bib21","doi-asserted-by":"crossref","first-page":"j116","DOI":"10.1136\/bmj.j116","article-title":"Rethinking brief interventions for alcohol in general practice","volume":"356","author":"McCambridge","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.mcna.2018.02.007_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jsat.2017.04.006","article-title":"Documented brief intervention not associated with resolution of unhealthy alcohol use one year later among VA patients living with HIV","volume":"78","author":"Williams","year":"2017","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"5","key":"10.1016\/j.mcna.2018.02.007_bib23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamainternmed.2018.0388","article-title":"Alcohol-Related Nurse Care Management in Primary Care: A Randomized Clinical Trial","volume":"178","author":"Bradley","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.mcna.2018.02.007_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1940-0640-8-12","article-title":"Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration","volume":"8","author":"Del Re","year":"2013","journal-title":"Addict Sci Clin Pract"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.007_bib25","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1176\/ps.2010.61.4.392","article-title":"Pharmacotherapy of alcohol use disorders in the Veterans Health Administration","volume":"61","author":"Harris","year":"2010","journal-title":"Psychiatr Serv"},{"issue":"7","key":"10.1016\/j.mcna.2018.02.007_bib26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1176\/appi.ps.201000553","article-title":"Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence","volume":"63","author":"Harris","year":"2012","journal-title":"Psychiatr Serv"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.007_bib27","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.addbeh.2013.05.006","article-title":"Long-acting injectable depot naltrexone use in the Veterans' Health Administration: a national study","volume":"39","author":"Marienfeld","year":"2014","journal-title":"Addict Behav"},{"issue":"11","key":"10.1016\/j.mcna.2018.02.007_bib28","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1097\/01.ALC.0000095861.43232.19","article-title":"Use of naltrexone in the treatment of alcoholism nationally in the Department of Veterans Affairs","volume":"27","author":"Petrakis","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"issue":"17","key":"10.1016\/j.mcna.2018.02.007_bib29","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.007_bib30","first-page":"8","article-title":"Topiramate in the treatment of alcohol dependence: a meta-analysis","volume":"38","author":"Arbaizar","year":"2010","journal-title":"Actas Esp Psiquiatr"},{"issue":"14","key":"10.1016\/j.mcna.2018.02.007_bib31","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.007_bib32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","article-title":"Gabapentin treatment for alcohol dependence: a randomized clinical trial","volume":"174","author":"Mason","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"18","key":"10.1016\/j.mcna.2018.02.007_bib33","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.007_bib34","first-page":"131","article-title":"The promises and pitfalls of digital technology in its application to alcohol treatment","volume":"36","author":"Muench","year":"2014","journal-title":"Alcohol Res"},{"issue":"3","key":"10.1016\/j.mcna.2018.02.007_bib35","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.007_bib36","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.007_bib37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2149","article-title":"Primary care-based models for the treatment of opioid use disorder: a scoping review","volume":"166","author":"Korthuis","year":"2017","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.mcna.2018.02.007_bib38","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"10118","key":"10.1016\/j.mcna.2018.02.007_bib39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2018.02.007_bib40","volume":"vol. 2017","author":"Macrae","year":"2015"},{"issue":"16","key":"10.1016\/j.mcna.2018.02.007_bib41","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial","volume":"313","author":"D'Onofrio","year":"2015","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.mcna.2018.02.007_bib42","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jamainternmed.2014.2556","article-title":"Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial","volume":"174","author":"Liebschutz","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.mcna.2018.02.007_bib43","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s11606-017-4077-z","article-title":"Inpatient addiction consultation for hospitalized patients increases post-discharge abstinence and reduces addiction severity","volume":"32","author":"Wakeman","year":"2017","journal-title":"J\u00a0Gen Intern Med"},{"issue":"5","key":"10.1016\/j.mcna.2018.02.007_bib44","doi-asserted-by":"crossref","first-page":"339","DOI":"10.12788\/jhm.2736","article-title":"Planning and designing the improving addiction care team (IMPACT) for hospitalized adults with substance use disorder","volume":"12","author":"Englander","year":"2017","journal-title":"J\u00a0Hosp Med"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.007_bib45","first-page":"254","article-title":"Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction","volume":"5","author":"Kraus","year":"2011","journal-title":"J\u00a0Addict Med"},{"issue":"1\u20132","key":"10.1016\/j.mcna.2018.02.007_bib46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugalcdep.2009.03.020","article-title":"Comparing overdose mortality associated with methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"10.1016\/j.mcna.2018.02.007_bib47","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.007_bib48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence","volume":"355","author":"Fiellin","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.mcna.2018.02.007_bib49","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/jat\/22.6.430","article-title":"Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities","volume":"22","author":"Tracqui","year":"1998","journal-title":"J\u00a0Anal Toxicol"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.007_bib50","first-page":"193","article-title":"Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers","volume":"92","author":"Haddad","year":"2015","journal-title":"J\u00a0Urban Health"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2018.02.007_bib51","doi-asserted-by":"crossref","first-page":"A63","DOI":"10.1186\/1940-0640-10-S1-A63","article-title":"A\u00a0collaborative opioid prescribing (CoOP) model linking opioid treatment programs with office-based buprenorphine providers","volume":"10","author":"Stoller","year":"2015","journal-title":"Addict Sci Clin Pract"},{"issue":"5","key":"10.1016\/j.mcna.2018.02.007_bib52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","article-title":"Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience","volume":"171","author":"Alford","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mcna.2018.02.007_bib53","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jsat.2015.06.010","article-title":"Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts collaborative care model in community health centers","volume":"60","author":"LaBelle","year":"2016","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"10","key":"10.1016\/j.mcna.2018.02.007_bib54","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jamainternmed.2017.3947","article-title":"Collaborative care for opioid and alcohol use disorders in primary care: the SUMMIT randomized clinical trial","volume":"177","author":"Watkins","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.mcna.2018.02.007_bib55","unstructured":"Patient-Centered Primary Care Collaborative. Vermont hub and spokes health homes statewide. Available at: www.pcpcc.org\/initiate\/vermont-hub-and-spokes-health-homes. Accessed September 22, 2017."},{"issue":"4","key":"10.1016\/j.mcna.2018.02.007_bib56","first-page":"286","article-title":"Vermont hub-and-spoke model of care for opioid use disorder: development, implementation, and impact","volume":"11","author":"Brooklyn","year":"2017","journal-title":"J\u00a0Addict Med"},{"issue":"6","key":"10.1016\/j.mcna.2018.02.007_bib57","first-page":"415","article-title":"Group medication management for buprenorphine\/naloxone in opioid-dependent veterans","volume":"8","author":"Berger","year":"2014","journal-title":"J\u00a0Addict Med"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.007_bib58","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/08897077.2014.998400","article-title":"Feasibility of implementing shared medical appointments (SMAs) for office-based opioid treatment with buprenorphine: a pilot study","volume":"36","author":"Suzuki","year":"2015","journal-title":"Subst Abus"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.007_bib59","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/08897077.2017.1356792","article-title":"Why use group visits for opioid use disorder treatment in primary care? A patient-centered qualitative study","volume":"39","author":"Sokol","year":"2018","journal-title":"Subst Abus"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.007_bib60","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/08897077.2015.1129388","article-title":"Project ECHO (Extension for Community Healthcare Outcomes): a new model for educating primary care providers about treatment of substance use disorders","volume":"37","author":"Komaromy","year":"2016","journal-title":"Subst Abus"},{"key":"10.1016\/j.mcna.2018.02.007_bib61","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.drugalcdep.2017.01.048","article-title":"The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting","volume":"176","author":"Eibl","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.007_bib62","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/10550887.2015.1127716","article-title":"Text message content preferences to improve buprenorphine maintenance treatment in primary care","volume":"35","author":"Tofighi","year":"2016","journal-title":"J\u00a0Addict Dis"},{"key":"10.1016\/j.mcna.2018.02.007_bib63","unstructured":"LifeSpring Health Systems. About us: locations. 2016. Available at: www.lifespringhealthsystems.org\/about-us\/locations. Accessed September 22, 2017."},{"issue":"4","key":"10.1016\/j.mcna.2018.02.007_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006754.pub3","article-title":"Anticonvulsants for cocaine dependence","author":"Minozzi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.mcna.2018.02.007_bib65","article-title":"Dopamine agonists for the treatment of cocaine dependence","author":"Minozzi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.mcna.2018.02.007_bib66","article-title":"Antipsychotic medications for cocaine dependence","author":"Indave","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.mcna.2018.02.007_bib67","article-title":"Antidepressants for cocaine dependence and problematic cocaine use","author":"Pani","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.007_bib68","article-title":"Disulfiram for the treatment of cocaine dependence","author":"Pani","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.007_bib69","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.drugpo.2015.01.002","article-title":"Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: a comprehensive narrative overview of English-language studies","volume":"26","author":"Fischer","year":"2015","journal-title":"Int J Drug Policy"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.007_bib70","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1176\/appi.ajp.2007.06111851","article-title":"A\u00a0meta-analytic review of psychosocial interventions for substance use disorders","volume":"165","author":"Dutra","year":"2008","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.007_bib71","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1151\/ascp084228","article-title":"The search for medications to treat stimulant dependence","volume":"4","author":"Kampman","year":"2008","journal-title":"Addict Sci Clin Pract"},{"issue":"6","key":"10.1016\/j.mcna.2018.02.007_bib72","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1365-2125.2010.03639.x","article-title":"Pharmacological approaches to methamphetamine dependence: a focused review","volume":"69","author":"Karila","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.007_bib73","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/add.13950","article-title":"Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial","volume":"113","author":"Coffin","year":"2018","journal-title":"Addiction"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2018.02.007_bib74","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1360-0443.2006.01774.x","article-title":"Contingency management: an evidence-based component of methamphetamine use disorder treatments","volume":"102","author":"Roll","year":"2007","journal-title":"Addiction"},{"issue":"11","key":"10.1016\/j.mcna.2018.02.007_bib75","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1176\/ajp.2006.163.11.1993","article-title":"Contingency management for the treatment of methamphetamine use disorders","volume":"163","author":"Roll","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.007_bib76","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drugalcdep.2006.03.005","article-title":"Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence","volume":"85","author":"Shoptaw","year":"2006","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.mcna.2018.02.007_bib77","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11524-014-9870-y","article-title":"Community-based harm reduction substance abuse treatment with methamphetamine-using men who have sex with men","volume":"91","author":"Carrico","year":"2014","journal-title":"J Urban Health"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.007_bib78","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/00918369.2014.865459","article-title":"Getting Off: development of a model program for gay and bisexual male methamphetamine users","volume":"61","author":"Reback","year":"2014","journal-title":"J Homosex"},{"key":"10.1016\/j.mcna.2018.02.007_bib79","series-title":"The national HIV\/AIDS strategy: updated to 2020","year":"2015"},{"key":"10.1016\/j.mcna.2018.02.007_bib80","series-title":"Implementing comprehensive HIV and HCV programmes with people who inject drugs: practical guidance for collaborative interventions","year":"2017"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.007_bib81","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1530-0277.2011.01601.x","article-title":"Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone","volume":"36","author":"Tetrault","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.007_bib82","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jsat.2014.02.008","article-title":"An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone","volume":"47","author":"Vagenas","year":"2014","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"6","key":"10.1016\/j.mcna.2018.02.007_bib83","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/add.13753","article-title":"Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot\/feasibility randomized trial","volume":"112","author":"Korthuis","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.mcna.2018.02.007_bib84","unstructured":"Edelman EJ, Moore B, Holt S, et\u00a0al. The impact of injectable naltrexone on antiretroviral therapy adherence, HIV viral load, and drinking in HIV-positive heavy drinkers. Paper presented at: Research Society on Alcoholism. Denver, CO, June 26, 2017."},{"issue":"6","key":"10.1016\/j.mcna.2018.02.007_bib85","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1177\/0145445506288229","article-title":"HAART adherence strategies for methadone clients who are HIV-positive: a treatment manual for implementing contingency management and medication coaching","volume":"30","author":"Haug","year":"2006","journal-title":"Behav Modif"},{"key":"10.1016\/j.mcna.2018.02.007_bib86","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cct.2016.11.008","article-title":"The Starting Treatment for Ethanol in Primary care Trials (STEP Trials): Protocol for Three Parallel Multi-Site Stepped Care Effectiveness Studies for Unhealthy Alcohol Use in HIV-Positive Patients","volume":"52","author":"Edelman","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.mcna.2018.02.007_bib87","unstructured":"Edelman EJ, Maisto SA, Hansen NB, et al. Integrated stepped care to address moderate alcohol use among HIV-positive patients with liver disease: Results from a randomized controlled clinical trial. Presented as an oral presentation at INEBRIA, September 15, 2017, New York, New York."},{"key":"10.1016\/j.mcna.2018.02.007_bib88","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.drugalcdep.2017.01.018","article-title":"Among patients with unhealthy alcohol use, those with HIV are less likely than those without to receive evidence-based alcohol-related care: a national VA study","volume":"174","author":"Williams","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.007_bib89","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.drugalcdep.2016.01.015","article-title":"HIV primary care providers\u2013Screening, knowledge, attitudes and behaviors related to alcohol interventions","volume":"161","author":"Chander","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2018.02.007_bib90","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/QAI.0b013e3182097537","article-title":"Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine\/naloxone","volume":"56","author":"Fiellin","year":"2011","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2018.02.007_bib91","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1097\/QAI.0b013e31820a8226","article-title":"Integration of buprenorphine\/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative","volume":"56","author":"Weiss","year":"2011","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2018.02.007_bib92","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1097\/QAI.0b013e318209751e","article-title":"HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine\/naloxone treatment within HIV clinical care settings: results from a multisite study","volume":"56","author":"Altice","year":"2011","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.mcna.2018.02.007_bib93","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.drugalcdep.2014.03.006","article-title":"The impact of buprenorphine\/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients","volume":"139","author":"Edelman","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.007_bib94","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jsat.2012.07.011","article-title":"Brief versus extended counseling along with buprenorphine\/naloxone for HIV-infected opioid dependent patients","volume":"43","author":"Tetrault","year":"2012","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2018.02.007_bib95","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1097\/QAI.0b013e318209754c","article-title":"Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics","volume":"56","author":"Korthuis","year":"2011","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"Suppl 1","key":"10.1016\/j.mcna.2018.02.007_bib96","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1097\/QAI.0b013e31820bc9a5","article-title":"Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine","volume":"56","author":"Korthuis","year":"2011","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.007_bib97","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/apc.2013.0179","article-title":"Patient perspectives of an integrated program of medical care and substance use treatment","volume":"28","author":"Drainoni","year":"2014","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.mcna.2018.02.007_bib98","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jsat.2015.07.007","article-title":"Engagement and substance dependence in a primary care-based addiction treatment program for people infected with HIV and people at high-risk for HIV infection","volume":"59","author":"Walley","year":"2015","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.mcna.2018.02.007_bib99","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jsat.2017.03.001","article-title":"Cocaine-using substance abuse treatment patients with and without HIV respond well to contingency management treatment","volume":"77","author":"Burch","year":"2017","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.007_bib100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1037\/a0016778","article-title":"Group-based randomized trial of contingencies for health and abstinence in HIV patients","volume":"78","author":"Petry","year":"2010","journal-title":"J\u00a0Consult Clin Psychol"},{"issue":"7","key":"10.1016\/j.mcna.2018.02.007_bib101","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s10461-013-0416-1","article-title":"A\u00a0study of financial incentives to reduce plasma HIV RNA among patients in care","volume":"17","author":"Farber","year":"2013","journal-title":"AIDS Behav"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.007_bib102","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/dar.12271","article-title":"Systematic review of interventions to reduce problematic alcohol use in men who have sex with men","volume":"35","author":"Wray","year":"2016","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.mcna.2018.02.007_bib103","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2017.01.026","article-title":"Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community","volume":"174","author":"Springer","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"10.1016\/j.mcna.2018.02.007_bib104","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-159-9-201311050-00005","article-title":"Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009","volume":"159","author":"Binswanger","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mcna.2018.02.007_bib105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jsat.2017.04.002","article-title":"Extended-release naltrexone for opioid use disorder started during or following incarceration","volume":"85","author":"Lincoln","year":"2018","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"13","key":"10.1016\/j.mcna.2018.02.007_bib106","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"N\u00a0Engl J Med"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712518300117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712518300117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T06:02:18Z","timestamp":1751695338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712518300117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":106,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0025712518300117"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2018.02.007","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Office-Based Addiction Treatment in Primary Care","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2018.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}